エピソード

  • Key Findings of the NIAGARA and HIMALAYA Trials
    2024/11/08
    In this episode of the Pharmaceutical Executive podcast, Shubh Goel, Head of Immuno-Oncology and Gastrointestinal Tumors, US Oncology Business Unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer, and much more.


    続きを読む 一部表示
    13 分
  • Fake Weight Loss Drugs: Growing Threat to Consumer Health
    2024/10/25
    UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss:
    • Counterfeit weight loss drugs (particularly fake Ozempic) and potential health risks
    • What can be done to raise awareness among consumers about the dangers of counterfeit medications
    • Ways increase access to legitimate weight loss medications, especially for those in underserved communities
    • and much more!
    続きを読む 一部表示
    21 分
  • A Different Approach to Dermatology Care
    2024/09/23
    Brian Hillberdink, EVP, LEO Pharma and President of LEO Pharma's US affiliate, discusses how is they're positioning to capitalize on the unmet needs in other specific therapeutic areas, their approach to orphan drug development, challenges and opportunities adapting to the US market, and more.
    続きを読む 一部表示
    15 分
  • Beyond the Birthrate: The Societal Costs of Maternal Morality
    2024/09/06
    In this episode of the Pharmaceutical Executive podcast, Charlotte Owens, MD, FACOG, Head of Medical Affairs and Outcomes Research at Organon discusses:
    • The broader societal implications of these maternal health issues highlighted in The Commonwealth Fund study
    • The most critical changes needed to close the gaps in R&D for maternal health solutions and how feasible they are to make
    • Specific efforts Organon is undertaking to invest in research, education, and its pipeline to focus on critical areas of need in maternal health
    • How her in-practice experience as an OB-GYN are informing Organon's strategic approach to addressing maternal health challenges
    • and more!
    続きを読む 一部表示
    16 分
  • Empty Shelves, Urgent Solutions
    2024/08/05
    Michael Abrams, Managing Partner at Numerof & Associates discusses pharmacy deserts and the main factors that are contributing to the closures of both large and independent pharmacies, what alternative solutions can help ensure continued access to medications for all Americans (particularly those in underserved communities), some potential long term consequences if these pharmacy closures continue, and so much more
    続きを読む 一部表示
    19 分
  • The Weight-Loss Gold Rush: Legal and Regulatory Implications
    2024/07/11
    Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses:
    • Top legal and regulatory concerns for investors considering when financing companies developing or marketing GLP-1 drugs
    • How the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs
    • What needs to be done for GLP-1s to be covered
    • Steps companies developing weight-loss medications should take to ensure responsible and ethical practice
    • Advice for investors and financiers who are considering entering the weight-loss medication market
    続きを読む 一部表示
    17 分
  • Healthcare Marketing Strategies for Reaching Diverse Audiences
    2024/05/14
    Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.

    Link to Honeycomb Health video: https://www.pharmexec.com/view/going-beyond-visuals-to-connect-with-diverse-audiences
    続きを読む 一部表示
    13 分
  • A Decade in the Anti-Obesity Arena
    2024/04/30
    Currax Pharmaceuticals CEO, George Hampton discusses what patient success has looked like for their oral anti-obesity medication, how expanded access can help with the world's obesity epidemic, when prices should come down, and much more.
    続きを読む 一部表示
    23 分